Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−29.69 MXN
−1.50 B MXN
7.24 M MXN
70.48 M
About Altimmune, Inc.
Sector
Industry
CEO
Vipin K. Garg
Website
Headquarters
Gaithersburg
Founded
1997
FIGI
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ALT1 is 119.25 MXN — it has decreased by −8.27% in the past 24 hours. Watch ALTIMMUNE, INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange ALTIMMUNE, INC stocks are traded under the ticker ALT1.
We've gathered analysts' opinions on ALTIMMUNE, INC future price: according to them, ALT1 price has a max estimate of 509.05 MXN and a min estimate of 181.80 MXN. Watch ALT1 chart and read a more detailed ALTIMMUNE, INC stock forecast: see what analysts think of ALTIMMUNE, INC and suggest that you do with its stocks.
ALT1 stock is 10.20% volatile and has beta coefficient of 3.04. Track ALTIMMUNE, INC stock price on the chart and check out the list of the most volatile stocks — is ALTIMMUNE, INC there?
Today ALTIMMUNE, INC has the market capitalization of 9.71 B, it has decreased by −3.35% over the last week.
Yes, you can track ALTIMMUNE, INC financials in yearly and quarterly reports right on TradingView.
ALTIMMUNE, INC is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
ALT1 earnings for the last quarter are −6.42 MXN per share, whereas the estimation was −6.39 MXN resulting in a −0.41% surprise. The estimated earnings for the next quarter are −7.04 MXN per share. See more details about ALTIMMUNE, INC earnings.
ALTIMMUNE, INC revenue for the last quarter amounts to 91.71 K MXN, despite the estimated figure of 13.10 K MXN. In the next quarter, revenue is expected to reach 14.07 K MXN.
ALT1 net income for the last quarter is −451.94 M MXN, while the quarter before that showed −404.28 M MXN of net income which accounts for −11.79% change. Track more ALTIMMUNE, INC financial stats to get the full picture.
No, ALT1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 6, 2024, the company has 59.00 employees. See our rating of the largest employees — is ALTIMMUNE, INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALTIMMUNE, INC EBITDA is −1.76 B MXN, and current EBITDA margin is −19.49 K%. See more stats in ALTIMMUNE, INC financial statements.
Like other stocks, ALT1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALTIMMUNE, INC stock right from TradingView charts — choose your broker and connect to your account.